Kämpgen E - Search Results

1

Acute generalized exanthematous pustulosis following oral nystatin therapy: a report of three cases.

Küchler A, Hamm H, Weidenthaler-Barth B, Kämpgen E, Bröcker EB. Küchler A, et al. Among authors: kampgen e. Br J Dermatol. 1997 Nov;137(5):808-11. Br J Dermatol. 1997. PMID: 9415247

2

Dendritic cell activation by danger and antigen-specific T-cell signalling.

McLellan AD, Bröcker EB, Kämpgen E. McLellan AD, et al. Among authors: kampgen e. Exp Dermatol. 2000 Oct;9(5):313-22. doi: 10.1034/j.1600-0625.2000.009005313.x. Exp Dermatol. 2000. PMID: 11016851 Review.

3

Classical chemotherapy for metastatic melanoma.

Becker JC, Kämpgen E, Bröcker E. Becker JC, et al. Among authors: kampgen e. Clin Exp Dermatol. 2000 Sep;25(6):503-8. doi: 10.1046/j.1365-2230.2000.00690.x. Clin Exp Dermatol. 2000. PMID: 11044186 Review.

4

Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.

Terheyden P, Becker JC, Kämpgen E, Bröcker EB. Terheyden P, et al. Among authors: kampgen e. Melanoma Res. 2000 Oct;10(5):475-82. doi: 10.1097/00008390-200010000-00010. Melanoma Res. 2000. PMID: 11095409 Clinical Trial.

5

Cross-reactive type IV hypersensitivity reactions to benzodiazepines revealed by patch testing.

Kämpgen E, Bürger T, Bröcker EB, Klein CE. Kämpgen E, et al. Contact Dermatitis. 1995 Nov;33(5):356-7. doi: 10.1111/j.1600-0536.1995.tb02060.x. Contact Dermatitis. 1995. PMID: 8565501 No abstract available.

6

Severe bullous drug reactions treated successfully with cyclophosphamide.

Trautmann A, Klein CE, Kämpgen E, Bröcker EB. Trautmann A, et al. Among authors: kampgen e. Br J Dermatol. 1998 Dec;139(6):1127-8. doi: 10.1046/j.1365-2133.1998.2576n.x. Br J Dermatol. 1998. PMID: 9990397 No abstract available.

7

Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis.

Terheyden P, Siedel C, Merkel A, Kämpgen E, Bröcker EB, Becker JC. Terheyden P, et al. Among authors: kampgen e. J Invest Dermatol. 1999 Jun;112(6):899-902. doi: 10.1046/j.1523-1747.1999.00607.x. J Invest Dermatol. 1999. PMID: 10383736 Free article.

8

[Cell therapy with dendritic cells].

Kämpgen E, Becker J, Bröcker EB. Kämpgen E, et al. Internist (Berl). 2001 Oct;42(10):1314-20. doi: 10.1007/s001080170053. Internist (Berl). 2001. PMID: 11688150 Review. German. No abstract available.

9

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2.

Becker JC, Terheyden P, Kämpgen E, Wagner S, Neumann C, Schadendorf D, Steinmann A, Wittenberg G, Lieb W, Bröcker EB. Becker JC, et al. Among authors: kampgen e. Br J Cancer. 2002 Oct 7;87(8):840-5. doi: 10.1038/sj.bjc.6600521. Br J Cancer. 2002. PMID: 12373596 Free PMC article. Clinical Trial.

10

Phospholipase A2 is secreted by murine keratinocytes after stimulation with IL-1 alpha and TNF-alpha.

Bastian BC, Schacht RJ, Kämpgen E, Bröcker EB. Bastian BC, et al. Among authors: kampgen e. Arch Dermatol Res. 1996 Mar;288(3):147-52. doi: 10.1007/BF02505824. Arch Dermatol Res. 1996. PMID: 8967783

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

92 results

Search Page

Filters